Literature DB >> 22783422

microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.

Dongqi Yu1, Huaijun Zhou, Qingying Xun, Xiaofeng Xu, Jingxian Ling, Yali Hu.   

Abstract

Despite improvements in treatment over the past few decades, endometrial cancer remains one of the most common causes of mortality in women and there is an urgent need for the development of targeted therapies. The aim of this study was to confirm the target gene of miR-103 in human endometrial cancer and investigate the biological functions in which miR-103 is involved through the regulation of the expression of its target gene. This study may provide useful data to gain a better understanding of the effect of miR-103 in tumor formation. miR-103 expression levels were measured using real-time quantitative PCR. The effect of miR-103 on tissue inhibitor of metalloproteinase 3 (TIMP-3) expression was assessed in endometrial cancer cell lines with a miR-103 inhibitor to decrease the level of miR-103 expression. Furthermore, the roles of miR-103 in cell growth and invasion were analyzed using miR-103 inhibitor-transfected cells. The level of expression of miR-103 decreased following transfection with the miR-103 inhibitor. miR-103 inhibitor transfection increased the activity of the luciferase reporter assay containing the TIMP-3 3'-untranslated region (UTR) construct and increased the levels of the TIMP-3 protein but not its mRNA in endometrial cancer cell lines. Finally, miR-103 inhibitor-transfected cells exhibited reduced cell growth and invasive characteristics. Our data suggested that miR-103 post-transcriptionally downregulates the expression of the tumor suppressor TIMP-3 and stimulates growth and invasion in endometrial cancer cell lines. This provides a possible therapeutic target that may upregulate TIMP-3 in endometrial cancer.

Entities:  

Year:  2012        PMID: 22783422      PMCID: PMC3392565          DOI: 10.3892/ol.2012.638

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer.

Authors:  Yaguang Xi; Reut Shalgi; Oystein Fodstad; Yitzhak Pilpel; Jingfang Ju
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

2.  MicroRNAs are involved in erythroid differentiation control.

Authors:  Gui-Hua Yang; Fang Wang; Jia Yu; Xiao-Shuang Wang; Jin-Yun Yuan; Jun-Wu Zhang
Journal:  J Cell Biochem       Date:  2009-06-01       Impact factor: 4.429

3.  MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein.

Authors:  Yanhui Lou; Xingsheng Yang; Fuling Wang; Zhumei Cui; Yu Huang
Journal:  Int J Mol Med       Date:  2010-12       Impact factor: 4.101

4.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Authors:  Bao Song; Chuanxi Wang; Jie Liu; Xingwu Wang; Liyan Lv; Ling Wei; Li Xie; Yan Zheng; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2010-03-27

5.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Authors:  K E Bachman; J G Herman; P G Corn; A Merlo; J F Costello; W K Cavenee; S B Baylin; J R Graff
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

6.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma.

Authors:  Yong Guo; Zhaoli Chen; Liang Zhang; Fang Zhou; Susheng Shi; Xiaoli Feng; Baozhong Li; Xin Meng; Xi Ma; Mingyong Luo; Kang Shao; Ning Li; Bin Qiu; Keith Mitchelson; Jing Cheng; Jie He
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

9.  Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.

Authors:  Nalinie S Wickramasinghe; Tissa T Manavalan; Susan M Dougherty; Krista A Riggs; Yong Li; Carolyn M Klinge
Journal:  Nucleic Acids Res       Date:  2009-03-05       Impact factor: 16.971

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  21 in total

1.  Profile of circulating microRNAs in fibromyalgia and their relation to symptom severity: an exploratory study.

Authors:  Jan L Bjersing; Maria I Bokarewa; Kaisa Mannerkorpi
Journal:  Rheumatol Int       Date:  2014-09-28       Impact factor: 2.631

2.  Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis.

Authors:  Audrey Villard; Lucien Marchand; Charles Thivolet; Sophie Rome
Journal:  J Mol Biomark Diagn       Date:  2015-10-02

3.  MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2.

Authors:  Yong-Bin Zheng; Kuang Xiao; Gao-Chun Xiao; Shi-Lun Tong; Yu Ding; Qiu-Shuang Wang; Sheng-Bo Li; Zhi-Nan Hao
Journal:  Oncol Lett       Date:  2016-07-05       Impact factor: 2.967

4.  LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway.

Authors:  Dong Xue; Cuixing Zhou; Hao Lu; Renfang Xu; Xianlin Xu; Xiaozhou He
Journal:  Tumour Biol       Date:  2016-10-14

5.  Post-transcriptional Regulation of MMP16 and TIMP2 Expression via miR-382, miR-410 and miR-200b in Endometrial Cancer.

Authors:  Beata Rak; Dawid Mehlich; Filip Garbicz; Zofia Domosud; Wiktor Paskal; Janina M Marczewska; Paweł K Włodarski
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

6.  MicroRNA-103a inhibits gastric cancer cell proliferation, migration and invasion by targeting c-Myb.

Authors:  Jinlong Liang; Xianfeng Liu; Hongpeng Xue; Bing Qiu; Bin Wei; Kan Sun
Journal:  Cell Prolif       Date:  2014-12-22       Impact factor: 6.831

Review 7.  Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy.

Authors:  Priyanka Prathipati; Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 8.  LncRNA-miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview.

Authors:  Abhishek Shetty; Thejaswini Venkatesh; Shama Prasada Kabbekodu; Rie Tsutsumi; Padmanaban S Suresh
Journal:  Arch Gynecol Obstet       Date:  2022-02-18       Impact factor: 2.493

Review 9.  Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors.

Authors:  Liqin Li; Heng Li
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

10.  Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.

Authors:  Prashant K Singh; Leah Preus; Qiang Hu; Li Yan; Mark D Long; Carl D Morrison; Mary Nesline; Candace S Johnson; Shahriar Koochekpour; Manish Kohli; Song Liu; Donald L Trump; Lara E Sucheston-Campbell; Moray J Campbell
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.